Hemostasis, Platelet Disorders, von Willebrand Disease, Hemophilia and DIC

Connect platelet function, coagulation-factor defects, diagnostic patterns and treatment principles into one rapid-revision framework.

1. THE TOPIC IN ONE CONNECTED FLOW

Hemostasis depends on an effective platelet plug followed by fibrin stabilization. Platelet disorders mainly disturb primary hemostasis, whereas hemophilia affects secondary hemostasis. von Willebrand factor links both processes, while DIC causes widespread activation and consumption of several hemostatic components at the same time.

Vascular Injury

Subendothelial collagen becomes exposed.

→

Primary Hemostasis

vWF → GPIb adhesion → platelet activation → GPIIb/IIIa–fibrinogen aggregation.

→

Secondary Hemostasis

Intrinsic and extrinsic pathways activate factor X → thrombin → fibrin.

→

Stable Clot

Fibrin reinforces the platelet plug and factor XIII stabilizes the fibrin network.

Platelet / vWF branch

Thrombocytopenia or defective vWF
→
impaired primary hemostasis
→
petechiae, mucosal bleeding or prolonged bleeding after minor procedures
→
platelet count and vWF studies help identify the defect.

Hemophilia branch

Factor VIII or IX deficiency
→
impaired intrinsic coagulation
→
inadequate fibrin stabilization
→
deep bleeding and hemarthrosis
→
prolonged aPTT with factor assay confirmation.

DIC branch

Severe triggering disorder
→
systemic thrombin generation
→
fibrin microthrombi
→
platelet and factor consumption plus secondary fibrinolysis
→
thrombosis, bleeding and organ dysfunction.

Therapeutic connection:
Factor VIII deficiency → factor VIII replacement;
factor IX deficiency → factor IX replacement;
selected mild hemophilia A → desmopressin;
excessive fibrin breakdown → antifibrinolytic therapy;
inadequate platelet production → oprelvekin support.

2. KEY CLINICAL CONNECTIONS

Mucocutaneous bleeding → identify the primary-hemostasis defect

Low platelet count
→
think thrombocytopenia/ITP.
Normal platelet count with abnormal vWF quantity or function
→
supports von Willebrand disease.

Deep bleeding → connect pattern with coagulation testing

Hemarthrosis or muscle hematoma
→
secondary-hemostasis defect
→
prolonged aPTT with normal PT
→
factor VIII or IX assay distinguishes hemophilia A from B.

Bleeding plus microvascular injury → consider consumption

Thrombocytopenia + prolonged PT/aPTT + reduced fibrinogen + increased D-dimer
→
widespread coagulation and fibrinolysis
→
DIC.

Match the treatment to the defective step

Desmopressin
→
increased vWF and factor VIII release in selected mild hemophilia A;
antifibrinolytics
→
reduced fibrin breakdown;
oprelvekin
→
megakaryocyte stimulation and increased platelet production.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ vWF bridges collagen to platelet GPIb → defective vWF impairs platelet adhesion → mucocutaneous bleeding.

ITP autoantibodies coat platelet glycoproteins → splenic macrophage clearance → isolated thrombocytopenia with preserved coagulation tests.

TTP/HUS form platelet-rich microthrombi → platelet consumption plus mechanical red-cell fragmentation → thrombocytopenia with microangiopathic hemolysis.

⭐ Factor VIII or IX deficiency → intrinsic pathway impairment → prolonged aPTT → deep bleeding and hemarthrosis.

Type 1 vWD → partial quantitative deficiency; Type 2 → qualitative dysfunction; Type 3 → severe quantitative deficiency.

⭐ DIC causes both clotting and bleeding → fibrin microthrombi impair organ perfusion while consumption of platelets and factors produces hemorrhage.

Tranexamic acid / aminocaproic acid → reduced plasmin-mediated fibrinolysis → greater clot stability; excessive clot preservation raises concern for thrombosis.

⭐ Therapy follows the defect: hemophilia A → factor VIII ± desmopressin in selected mild disease; hemophilia B → factor IX; reduced platelet production → oprelvekin.

AIM Exam Trap:
Petechiae and mucosal bleeding point toward a platelet/vWF problem, whereas recurrent hemarthrosis and deep muscle bleeding point toward a coagulation-factor defect. DIC differs because it can produce both thrombosis and bleeding through systemic coagulation activation and consumption.

Hemostasis, Platelet Disorders, von Willebrand Disease, Hemophilia and DIC

1. THE TOPIC IN ONE CONNECTED FLOW

2. KEY CLINICAL CONNECTIONS

3. AIM HIGH-YIELD INTEGRATION REVIEW

Install AIM App